Related Experiment Videos
Molecular clonal analysis of recurrent bladder cancer
Kerstin Junker1, Michael Wolf, Jörg Schubert
1Department of Urology, Lessingstr. 1, D-07743 Jena, Germany. kerstin.junker@med.uni-jena.de
Oncology Reports
|July 14, 2005
Summary
Most bladder cancer recurrences originate from a single clone, suggesting early tumor cell spread. This monoclonal origin indicates that early post-surgery instillation therapy is crucial for managing recurrent bladder cancer.
Area of Science:
- Oncology
- Molecular Genetics
- Urology
Background:
- Recurrent bladder cancer necessitates understanding its origin for optimal patient therapy.
- The clonal origin of bladder cancer recurrence remains a subject of debate.
Purpose of the Study:
- To determine the clonal origin of recurrent bladder tumors.
- To utilize molecular genetic markers for defining tumor recurrence pathways.
Main Methods:
- Investigated 30 recurrent bladder cancer cases using microsatellite analysis.
- Employed 4 markers on chromosome 9 and automated DNA sequencing.
- Analyzed loss of heterozygosity (LOH) patterns across multiple tumor recurrences per case.
Main Results:
- Loss of heterozygosity (LOH) was detected in 25 out of 30 cases.
- Identical LOH patterns, affecting the same allele, were observed in 20 cases, indicating monoclonal origin.
- Four cases showed different LOH patterns, and one had alterations in different markers; five cases had no detected alterations.
Conclusions:
- The majority of bladder cancer recurrences exhibit a monoclonal origin.
- Recurrence is likely caused by the dissemination of cells from the primary tumor.
- Early instillation therapy after transurethral resection is recommended to prevent recurrence.